Illumina’s FDA-approved TruSight Oncology test will be reimbursed by CMS at $2,989.55 per test starting Jan. 1, 2026, enabling broader laboratory access to genomic profiling for Medicare beneficiaries.
The milestone was achieved across urgent care clinics in Georgia, Ohio, and South Carolina since February 2025.
Teams complete whole human genome sequencing and analysis in under four hours, demonstrating potential for same-day NICU workflows.
The quality management system certification confirms commitment to delivering consistent products and services to the scientific community.
The pathologist served as joint plaintiff in successful lawsuit challenging FDA regulation of LDTs as medical devices.
Lot-to-lot reagent inconsistencies can have significant effects on patient test results.
The laboratory services company updates full-year guidance following continued momentum in diagnostics and central laboratory businesses.
Analysis of international surveillance data shows rising resistance to last-line antibiotics, with significant regional variations in treatment outcomes.